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background: This study investigated the effectiveness of a specific antidote for dabigatran (aDabi-Fab) to reverse bleeding in a dabigatran 
anticoagulated pig trauma model.
methods: After ethical approval, male pigs (n=24) were given dabigatran etexilate for 3 days (30 mg/kg bid PO), the sham group (n=6) 
received placebo. To achieve supratherapeutic anticoagulation, dabigatran was infused for 90 min prior to injury on day 4 in anaesthetized pigs. 
A standardized blunt liver injury was inflicted by clamping forceps through the middle liver lobe. Following hemorrhagic shock, resuscitation was 
started 5 min after trauma with Ringer’s to compensate for blood loss (BL). BL was recorded 10 min post trauma, animals were then randomized 
(n=6/group) to a single injection of aDabi-Fab at 30, 60 or 120 mg/kg iv or vehicle. BL and hemodynamic variables were monitored over 4 h or until 
time of death.
results: Dabigatran levels were 1225 ± 324 ng/mL with no differences between groups prior to injury. BL in the non-anticoagulated sham animals 
was 432 ± 50 mL 10 min after injury and 700 ± 107 mL after 4 hrs (survival rate 100%). Anticoagulation with dabigatran resulted in significantly 
higher BL 10 min after injury (782 ± 37 mL, p<0.001). Mortality was 100%, with a mean survival time of 121 min. BL was 2834 ± 476 mL at 4 hrs. 
Bleeding was associated with severe shock indicated by increased lactate levels and a significant drop in hemoglobin and platelets (p<0.001). In 
contrast, treatment with aDabi-Fab was associated with a dose-dependent reduction in BL. The lowest dose of 30 mg/kg resulted in 17% mortality 
(1/6 animals) and BL was reduced by more than half (1705 ± 610 mL). BL was further reduced in animals receiving 60 (1077 ± 103 mL) or 120 
(1137 ± 121 mL) mg/kg aDabi-Fab (100% survival). Haemodynamic parameters and markers of shock were similar to pre-trauma levels in latter 
groups receiving aDabi-Fab. Clinically and macroscopically no adverse events were observed following treatment with aDabi-Fab.
conclusion: In this study aDabi-Fab effectively and safely reversed dabigatran anticoagulation, even under conditions of supratherapeutic 
dabigatran and life-threatening bleeding resulting from severe trauma.
